Myositis/myasthenia gravis caused by immune checkpoint inhibition: A report of two cases and a brief review of the literature
- Authors:
- Published online on: December 3, 2024 https://doi.org/10.3892/mi.2024.210
- Article Number: 11
-
Copyright : © Elavia et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Abstract
Introduction
Immune checkpoint inhibitors (ICIs) have emerged as critical tools in the treatment of various malignancies by harnessing the potential of the immune system to combat cancer cells (1,2), transforming cancer treatment in the era of precision medicine (2). FDA-approved drugs, such as cemiplimab, ipilimumab, nivolumab and pembrolizumab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) checkpoints, have had a profound effect on patients with various types of cancer, including melanoma, non-small cell lung cancer, renal cell cancer and classical Hodgkin lymphoma (3,4). Nivolumab and cemiplimab, monoclonal antibodies targeting PD-1, are notable ICIs that have demonstrated notable therapeutic efficacy. However, the use of ICIs is associated with the risk of developing immune-related adverse events (irAEs), which can affect diverse organ systems. These potentially include conditions, such as diabetes, hypothyroidism, adrenal insufficiency, interstitial pneumonia, colitis, renal impairment and liver dysfunction (5). Neurological adverse effects are rare, occurring in <3% of patients treated with ICIs, including axonal polyneuropathies, Guillain-Barré syndrome, myositis, myasthenia gravis (MG), posterior reversible encephalopathy syndrome, aseptic meningitis, enteric neuropathy, transverse myelitis, and autoimmune encephalitis (5,6). MG, an autoimmune neuromuscular junction transmission disorder characterized by fatigable muscle weakness, is a commonly reported irAE associated with ICI therapy (1). Nivolumab and cemiplimab-induced myositis/MG presents a clinical challenge due to its rarity and the need for prompt recognition and management to prevent life-threatening outcomes (2).
The present study describes the cases of 2 patients who developed myositis/MG following nivolumab and cemiplimab therapy, a 71-year-old male and a 66-year-old female. In addition, a brief review of the literature was performed. The present study aims to shed light on the clinical presentation, diagnostic-associated difficulties and therapeutic interventions encountered with this unique clinical condition.
Case report
Case 1
Case 1 involves a 71-year-old male with a previous medical history of hypertension, hyperlipidemia, obstructive sleep apnea, acid reflux disease and esophageal adenocarcinoma that had metastasized to the liver. He received a treatment regimen consisting of leucovorin, oxaliplatin and 5-fluorouracil (FOLFOX), along with nivolumab and radiotherapy, to address the esophageal cancer. At 5 weeks after commencing treatment with nivolumab, he presented to the authors' oncology service at the University of Alabama (UAB; Birmingham, AL, USA) with chief complaints of acute onset double vision, fatigable weakness and shortness of breath. His social history entailed the consumption of 1 beer weekly. He had no history of illicit drug abuse. He had quit smoking 33 years prior. His family history was positive for colon cancer in an aunt on his father's side of the family. His father had a history of heart valve disease and ischemic stroke. His mother had a history of coronary artery disease. He was empirically treated with 100 mg prednisone for elevated hepatic transaminases. Upon a physical examination, his vital signs were found to be stable and his oxygen saturation was 98% in room air. Upon a neurological examination, his speech was clear with good naming and repetition. A cranial nerve examination revealed right eye ptosis, impaired extraocular muscle movements in all directions, and proximal more than distal limb weakness. Deep tendon reflexes were preserved all over with down-going toes. An examination of his sensory and cerebellar functions did not reveal any notable findings. A further evaluation revealed elevated troponin levels peaking at 2,641 ng/ml (Fig. 1) with electrocardiogram changes suggestive of non-ST-elevated myocardial infarction (NSTEMI) and creatine kinase (CK) at 1,511 IU/l (Fig. 1). He was admitted to the hospital, and cardiology was consulted for his NSTEMI.
The new and acute onset symptoms during chemotherapy made it more likely to be immunotherapy-induced myositis/MG rather than a steroid induced myopathy case. The neurology and rheumatology teams were consulted thereafter due to a concern for ICI-induced myositis/MG. His Myasthenia Gravis Foundation of America (MGFA) classification was deemed to be class IIIa. His laboratory test results are listed in Table I. A nerve conduction study (NCS) and an electromyography (EMG) revealed evidence of mild axonal sensory and motor neuropathy with no evidence of myopathy. Repetitive nerve stimulation (RNS) testing did not reveal any decrement or facilitation response. A brain MRI with contrast did not reveal any notable findings or acute changes and did not reveal any brain metastases. The patient was commenced on high-dose prednisone at 1 g/kg/day for 3 days and then transitioned to prednisone at 2 mg/kg/day on day 3, and subsequently to methylprednisolone at 1,000 mg daily for 3 days due to a concern for immunotherapy-induced cardiotoxicity. The patient was also commenced on intravenous immunoglobulin (IVIG) as per the neurological recommendation due to the concern for generalized MG and/or myositis, despite negative EMG and serological testing. The condition of the patient clinically improved with decreased levels CK of 295 U/dl and troponin upon discharge (Fig. 1). He was discharged on 1 mg/kg/day (100 mg) of prednisone daily until his follow-up appointment with his oncologist, following which prednisone was tapered slowly over a period of 6 to 8 weeks.
After 2 weeks, he presented again to the UAB Medical Center for the third time in 2 months with worsening symptoms, including drooping of the right eyelid, double vision, shallow breathing, difficulty swallowing, proximal limb weakness, dysarthria and failure to thrive. A neurological examination revealed right eye ptosis, nasal speech, impaired extraocular muscle movement and fatigable proximal muscle weakness. These clinical findings raised a strong suspicion of an ongoing myasthenic process, particularly in the setting of continual decreasing levels of CK (98 U/dl). His hospital course was complicated, and his condition rapidly deteriorated. He was placed on intermittent bi-level-positive airway pressure support to improve his breathing effort (now MGFA class IVb, 8 weeks from the onset of his myositis/MG). He was commenced on plasmapheresis. However, the clinical condition of the patient only minimally improved in terms of truncal strength, swallowing and diaphragmatic weakness. The palliative care team engaged with the patient and family to address the goals of care. The patient and family desired to forgo further chemotherapy and return home with hospice care to maximize the quality of life in the remaining time. The patient passed away 1 month thereafter.
Case 2
Case 2 involves a 66-year-old female patient with a previous medical history of hypertension and hyperlipidemia who was commenced on cemiplimab therapy for metastatic squamous cell carcinoma at an outside cancer clinic. She received her first dose and within 10 days; she had generalized weakness, difficulty rising from a chair and walking with an unsteady gait. Over the following 2 weeks, she began to suffer from weakness in the proximal upper limbs, swallowing difficulties, dysarthria, diplopia and right eye ptosis. Her clinical image was consistent with MG, although tests for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) antibodies yielded negative results. She was empirically commenced on an immediate course of prednisone and pyridostigmine, although the latter was terminated due to diarrhea. Additionally, the patient received five doses of IVIG, without exhibiting a notable improvement in her symptoms. She was then referred to the UAB Medical Center for oncologic and neurologic management at 2 months from the initial dose of cemiplimab. Of note, she did not have any history of smoking, alcohol consumption, or illicit drug abuse. Her family history was negative for cancer or neurological disorders.
Upon an initial examination, she endorsed continued generalized weakness, a 28-pound weight loss due to dysphagia, voice changes and a difficulty with deep breathing. Her only therapeutic at the time was prednisone which had been tapered from 60 to 20 mg. A neurological examination revealed ptosis and a facial droop worse on the right side compared with the left side, 4/5 strength in the majority of the proximal muscle groups, normal reflexes, and intact all-modalities sensory examination (MGFA class IIIb, 7 weeks from the onset of myositis/MG). The results of her laboratory are presented in Table I. Given her facial asymmetry, a head CT scan was obtained, which did not reveal any notable findings. A brain MRI and c-spine with and without contrast were also non-informative (other than moderate cervical stenosis). A NCS and EMG revealed electrophysiologic evidence of diffuse irritable myopathy. RNS did not reveal a decremental response, yet concentric needle jitter analysis revealed all six pairs with increased jitter and an elevated mean consecutive difference of 69.2 msec, as can be seen with myasthenia gravis.
The patient completed five sessions of plasma exchange therapy over 10 days of hospital stay at the UAB Medical Center. She exhibited a gradual improvement in her symptoms and although she initially failed a swallow test, she was able to slowly advance her diet along with mirtazapine therapy to improve her appetite. On an outpatient follow-up at 1 week after discharge, she exhibited an improvement in her gait and speech. The patient continued to have difficulty with dysphagia, diplopia, and proximal weakness and prednisone was increased to 40 mg. She was then set up for an initiation of monthly outpatient combined plasma exchange with IVIG 1 week later. The last time she was seen at the UAB Outpatient Kirklin Clinic was 3 months later. She still had bilateral mild ptosis, diplopia when looking upwards (after ~10 sec) and to the right, and 4/5 muscle strength in the bilateral external arm rotators, hip flexor and abductor muscles (MGFA class IIa).
Discussion
The present study describes two cases of ICI-related myositis/MG. The first patient began to exhibit symptoms of myositis/MG 5 weeks after receiving nivolumab and progressed to MGFA class IV over a period of 8 weeks. The second case developed the disease only 10 days after taking one dose of cemiplimab and progressed to MGFA class III within 7 weeks. Both cases clearly reflect the aggressive nature of the disease compared to what is typically observed in autoimmune MG cases. In the first case, a poor outcome was observed with the commencement of steroid treatment, despite upgrading the treatment with IVIG and plasma exchange later. In the second case, a more proactive and sustained treatment approach, including IVIG and plasma exchange treatments followed by maintaining the same modalities on an outpatient basis, led to a more favorable outcome. In their study, Safa et al (7) reported that 63% of their 65 patients had a similar aggressive course developing moderate to severe muscle weakness (MGFA class III to V) following ICI with the vast majority of patients (96%) requiring hospitalization. The median time between ICI treatment initiation and the first MG symptom was 4 weeks (range, 6 days to 16 weeks) (7). Myositis was noted in more than one third of their patients and both of the patients in the present study developed serological or electrophysiological evidence of myositis. In the present study, the 1st patient developed myocarditis and the 2nd patient developed hepatitis, which were reported in 8 and 9% of the patients in the study by Safa et al (7), respectively. Another smaller cohort study demonstrated that 8 out of 10 reported patients developed the triad of MG, myositis and myocarditis (8). Typically, in regular cases of MG, classes IV/V are encountered in only 2-10% of cases and the time from onset to class IV/V status ranges between 2-3 years (9,10). Evidence of concurrent myositis exists in only 0.9% of typical MG cases (11).
Nivolumab and cemiplimab, the offending agents in both cases presented, are monoclonal antibodies that bind to PD-1 receptors, found on the surfaces of activated T-cells. They prevent the binding of tumor-secreted PD-1 ligands to the PD-1 receptor (4,12). Blocking the PD-1 receptor can enhance T-cell antitumor activity; however, this may also result in an increased CD8/CD4 ratio and reduced regulatory T-cell numbers (13). While ICIs have exhibited notable responses in a number of malignancies, they can cause irAEs (2). The exact mechanisms of irAEs are not yet fully understood; however, but they are c to stem from an imbalance between autoimmunity and immune tolerance. Immune checkpoints, such as PD-1 and CTLA-4 play a crucial role in maintaining self-tolerance and preventing autoimmunity. When these natural immune ‘brakes’ are released, this can lead to unchecked activated T-cells targeting self-antigens, the release of inflammatory cytokines, and ultimately, in inflammation and tissue damage, clinically presenting as autoimmune disorders (3,6). In a previous study, peripheral blood mononuclear cellular typing was performed before and after nivolumab treatment in a patient who developed MG/myositis/myocarditis, and revealed an increased expression of CD8 and cytolytic activity markers, whereas CD4 T-cell and T-regulatory cell activity were suppressed (14). An elevated CD8/CD4 ratio was reported in another patient with nivolumab-related MG/myositis (15). Other hypotheses have been proposed, including that the use of PD-1 inhibitors may lead to a pro-inflammatory cascade involving T-lymphocytes, interleukins (IL-2, IL-6, IL-17) and tumor necrosis factor-alpha, which may contribute to the development of MG. ICIs may also increase the availability of ligands for CD28, activating potentially self-reactive T-cells. Nivolumab could unmask latent autoimmunity toward the AChR that was not clinically manifest earlier (2). In the present study, case 1 also developed concurrent myocarditis after commencing treatment with PD-1 inhibitors. The pathophysiology of this overlap suggests that PD-1 expression on cardiomyocytes protects the myocardium during stress. When there is damage to the heart during ICI blockade, T-lymphocytes are less likely to attack cardiac antigens, and PD-1 is less likely to protect the heart (6,16).
In addition to the two largest case cohorts (7,8), herein, a review of the literature (Table II) (2,12,14,16-29) revealed 19 additional case reports published between 2014 and 2021. In their large cohorts, Safa et al (7) and Weaver et al (8) reported that ~1/3 of cases were seronegative when it came to MG antibodies. An additional five individual case reports revealed negative anti-AchR antibodies, all consistent with both of the cases described herein (12,23,26,27,29). Of note, 80-85% of individuals who suffer from de novo MG in general have AchR antibodies. In generalized MG patients who are seronegative for AChR antibodies, 50-70% test positive for MuSK antibodies. However, these antibodies are not always found in ICI-mediated MG, and when they are, they are much less common than in typical MG (6). Thus far, there are only four reported cases of anti-MuSK antibodies found in a patient with ICI-induced MG (7,8,16). This was linked to a very poor prognosis, resulting in severe respiratory muscle failure (7,8,16).
The overlap of MG with myositis creates a diagnostic challenge. NCS and EMG are often used for diagnosis; however, repetitive nerve stimulation testing is generally insensitive especially in ocular MG cases (6). It remains unclear whether elevated CK levels reflect a concurrent process or primary myositis predominantly involving the oculobulbar muscles (6). In the cases described herein, the fatigable component of weakness with the descending distribution favored a myasthenic process. However, the negative MG serologic and electrodiagnostic testing in case 1 in addition to the elevated levels of CK at time of onset favored a concomitant myopathic process.
Treatment considerations
For ICI-associated MG, treatment typically involves discontinuing the offending ICI. Earlier reports have indicated that patients who receive IVIG or plasma exchange as the initial treatment have higher rates of symptom improvement compared to those treated with only steroids (6-8). IVIG or plasma exchange are more effective when used as the first-line treatment option, as some patients deteriorate despite the second-line use of IVIG or plasma exchange after initial steroid treatment has failed (2,7). This pattern was also noted in the cases in the present study. Fatality due to ICI-associated MG has been reported in 20-38% of cases (2,6,7). Complete symptom resolution is relatively rare, and prognosis is guarded. In the first case described herein, the patient was discharged to hospice care with outpatient follow-up with a neurologist. Current recommendations indicate a trial of pyridostigmine with or without concurrent steroid therapy for patients with MGFA class I (ocular symptoms only) or class II (mild generalized weakness). A re-challenge with ICI can be considered in patients with MGFA class 1 or 2, as reported in two exceptional cases in the literature (6).
Clinical implications and challenges
Prior to initiating ICIs, it is crucial to screen patients for autoimmune diseases and analyze CK levels. Patients should be informed about the risk of developing irAEs (rheumatologic and neurologic), despite their low incidence rates. Based on the present case reports and previous data, a closely collaborating team comprising neurologists, rheumatologists and oncologists is necessary to diagnose and manage life-threatening adverse effects promptly and effectively (2,6). The cases described herein also underscore the importance of not relying solely on serological markers or electrodiagnostic testing, as this can lead to diagnostic delays with a potential impact on patient outcomes.
Limitations
The present case reports have limitations, including a lack of comprehensive understanding of the underlying pathophysiology of ICI-induced myositis/MG and the absence of standardized diagnostic criteria. Single-fiber EMG was not performed on the first patient as it was deemed to be technically challenging as the patient spent most of his hospital course in the ICU or the stepdown unit.
Conclusion
ICI medications have revolutionized cancer therapy. However, they are associated with the risk of developing irAEs, including myositis/MG, which present a unique set of diagnostic and management challenges. The causes of ICI-induced myositis/MG remain unclear and preclinical studies are required to elucidate the pathophysiology of these irAEs. There are several diagnostic challenges, including that this condition is rare and sometimes the serological markers and electrodiagnostic testing are both negative. The potentially associated myocarditis and hepatitis may render the diagnosis even more challenging and require a team from multiple disciplines to take care of such cases. Prompt recognition and intervention are essential in preventing severe morbidity and mortality in these patients, since the disease appears to be more aggressive than what is observed in typical MG cases. When someone has ICI-induced MG, they are usually treated by terminating the ICI that is causing it, commencing treatment with corticosteroids, and early treatment with IVIG and/or plasma exchange. Prospective longitudinal studies enrolling larger number of patients could define the true incidence of myositis/MG after ICI and differentiate those who had a subclinical autoimmunity that manifests only following exposure to ICI from new-onset disease. They could also better answer the question whether it is safe to reintroduce ICI treatment in a patient who was treated earlier from ICI induced myositis/MG, since the current safety data are all derived from case reports and small cohort studies. The two cases described herein underscore the importance of proactive approaches to monitoring and managing myositis/MG in ICI-treated patients, regardless of negative serological markers and electrodiagnostic testing. As the use of ICIs continues to expand in cancer therapy, healthcare providers need to be vigilant and well-informed about the potential of these multisystemic irAEs and be prepared to provide early and specific interventions to optimize patient outcomes.
Acknowledgements
Not applicable.
Funding
Funding: No funding was received.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
ZE, VJ, MK contributed to the conception, design, data collection and writing of the present case report. RL and AM were responsible for the treatment and management of the patient. ZE and MK confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
Verbal consents were obtained from the patients for their participation in the present study.
Patient consent for publication
Verbal consents were obtained from the patients for the publication of related information in the present study.
Competing interests
The authors declare that they have no competing interests.
References
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018.PubMed/NCBI View Article : Google Scholar | |
Tahir N, Mahboob A, Piao X, Ying G, Shrestha J, Sherchan R and Zahra F: Nivolumab, a Double-Edged Sword: A case report of nivolumab-induced myasthenia gravis. J Med Cases. 12:424–428. 2021.PubMed/NCBI View Article : Google Scholar | |
Wilgenhof S and Neyns B: Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 22:991–993. 2011.PubMed/NCBI View Article : Google Scholar | |
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H and Mauermann ML: Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 74:1216–1222. 2017.PubMed/NCBI View Article : Google Scholar | |
Hottinger AF: Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 29:806–812. 2016.PubMed/NCBI View Article : Google Scholar | |
Haugh AM, Probasco JC and Johnson DB: Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 19:479–488. 2020.PubMed/NCBI View Article : Google Scholar | |
Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, et al: Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature. J Immunother Cancer. 7(319)2019.PubMed/NCBI View Article : Google Scholar | |
Weaver JM, Dodd K, Knight T, Chaudhri M, Khera R, Lilleker JB, Roberts M, Lorigan P and Cooksley T: Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: A case series. Support Care Cancer. 31(518)2023.PubMed/NCBI View Article : Google Scholar | |
Grob D, Brunner N, Namba T and Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve. 37:141–149. 2008.PubMed/NCBI View Article : Google Scholar | |
Gummi RR, Kukulka NA, Deroche CB and Govindarajan R: Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 60:693–699. 2019.PubMed/NCBI View Article : Google Scholar | |
Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, et al: Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 66:1334–1338. 2009.PubMed/NCBI View Article : Google Scholar | |
Kang KH, Grubb W, Sawlani K, Gibson MK, Hoimes CJ, Rogers LR, Lavertu P and Yao M: Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. Am J Otolaryngol. 39:642–645. 2018.PubMed/NCBI View Article : Google Scholar | |
Kao JC, Brickshawana A and Liewluck T: Neuromuscular complications of programmed cell death-1 (PD-1) Inhibitors. Curr Neurol Neurosci Rep. 18(63)2018.PubMed/NCBI View Article : Google Scholar | |
Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, et al: Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 107:1055–1058. 2016.PubMed/NCBI View Article : Google Scholar | |
Chen YH, Liu FC, Hsu CH and Chian CF: Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report. Medicine (Baltimore). 96(e7350)2017.PubMed/NCBI View Article : Google Scholar | |
Fazel M and Jedlowski PM: Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma. Case Reports Immunol. 2019(2539493)2019.PubMed/NCBI View Article : Google Scholar | |
Liao B, Shroff S, Kamiya-Matsuoka C and Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 16:589–593. 2014.PubMed/NCBI View Article : Google Scholar | |
Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR and Sosman JA: Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 33:e122–e124. 2015.PubMed/NCBI View Article : Google Scholar | |
Loochtan AI, Nickolich MS and Hobson-Webb LD: Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve. 52:307–308. 2015.PubMed/NCBI View Article : Google Scholar | |
Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M and Ando Y: Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 78:119–122. 2016.PubMed/NCBI | |
Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ and Zappia M: Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve. 54:507–509. 2016.PubMed/NCBI View Article : Google Scholar | |
Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R and Uhara H: Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 46:86–88. 2016.PubMed/NCBI View Article : Google Scholar | |
Polat P and Donofrio PD: Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve. 54(507)2016.PubMed/NCBI View Article : Google Scholar | |
Chang E, Sabichi AL and Sada YH: Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother. 40:114–116. 2017.PubMed/NCBI View Article : Google Scholar | |
Chen JH, Lee KY, Hu CJ and Chung CC: Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review. Medicine (Baltimore). 96(e9262)2017.PubMed/NCBI View Article : Google Scholar | |
Veccia A, Kinspergher S, Grego E, Peterlana D, Berti A, Tranquillini E and Caffo O: Myositis and myasthenia during nivolumab administration for advanced lung cancer: A case report and review of the literature. Anticancer Drugs. 31:540–544. 2020.PubMed/NCBI View Article : Google Scholar | |
Jeyakumar N, Etchegaray M, Henry J, Lelenwa L, Zhao B, Segura A and Buja LM: The terrible triad of checkpoint inhibition: A case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Reports Immunol. 2020(5126717)2020.PubMed/NCBI View Article : Google Scholar | |
Canino F, Pugliese G, Baldessari C, Greco S, Depenni R and Dominici M: Cemiplimab- and nivolumab-induced myasthenia gravis: Two clinical cases. Tumori. 107:NP123–NP126. 2021.PubMed/NCBI View Article : Google Scholar | |
Bawek SJ, Ton R, McGovern-Poore M, Khoncarly B and Narvel R: Nivolumab-Induced myasthenia gravis concomitant with myocarditis, myositis, and hepatitis. Cureus. 13(e18040)2021.PubMed/NCBI View Article : Google Scholar |